Pipenzolate Bromide
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB13844 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 28 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | insomnia (disease) | KG + DL |
| 2 | neurocirculatory asthenia | KG + DL |
| 3 | irritable bowel syndrome | KG + DL |
| 4 | anxiety | KG + DL |
| 5 | enterocolitis (disease) | KG + DL |
| 6 | anxiety disorder | KG + DL |
| 7 | dysthymic disorder | KG + DL |
| 8 | sleep disorder, initiating and maintaining sleep | KG + DL |
| 9 | agoraphobia | KG + DL |
| 10 | autonomic nervous system disease | KG + DL |
| 11 | benign paroxysmal torticollis of infancy | KG + DL |
| 12 | juvenile onset Parkinson disease 19A | KG + DL |
| 13 | nephrogenic syndrome of inappropriate antidiuresis | KG + DL |
| 14 | headache disorder | KG + DL |
| 15 | osteoarthritis | KG + DL |
| 16 | common cold | KG + DL |
| 17 | dysautonomia | KG + DL |
| 18 | trigeminal autonomic cephalalgia | KG + DL |
| 19 | phaeochromocytoma | KG + DL |
| 20 | manic bipolar affective disorder | KG + DL |
| 21 | myositis fibrosa | KG + DL |
| 22 | idiopathic granulomatous myositis | KG + DL |
| 23 | inclusion body myositis | KG + DL |
| 24 | hereditary late onset Parkinson disease | KG + DL |
| 25 | acute intermittent porphyria | KG + DL |
| 26 | atypical juvenile parkinsonism | KG + DL |
| 27 | tendinitis | KG + DL |
| 28 | major affective disorder | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.